Announcement on the Approval for Manufacturing and Marketing Authorization of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product “AMCHEPRY” in Japan

Sumitomo Pharma Co. Ltd. published this content on March 06, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 06, 2026 at 00:28 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]